1. Emerging HIV Drug Resistance in the Resource-Poor World: Challenges and Strategies
- Author
-
Sahra Emamzadeh-Fard, Pouria Rouzrokh, Shooka Esmaeeli, SeyedAhmad SeyedAlinaghi, and Koosha Paydary
- Subjects
Resource poor ,medicine.medical_specialty ,business.industry ,Immunology ,Human immunodeficiency virus (HIV) ,Dermatology ,Drug resistance ,medicine.disease_cause ,Omics ,Virology ,VIROLOGIC FAILURE ,Infectious Diseases ,Pharmacotherapy ,ANTIRETROVIRAL AGENTS ,medicine ,Intensive care medicine ,business ,HIV drug resistance - Abstract
At the end of 2011, more than 8 million People Living with HIV (PLWH) were receiving Anti-retroviral Therapy (ART) in lowand middle-income countries [1]. Accordingly, the advent and extensive use of Highly Active Anti-retroviral Therapy (HAART) has dramatically reduced the mortality and morbidity associated with the HIV infection worldwide [2]. However, many factors such as missing doses of medications, interruptions in ART and mono-therapy in the pre-HAART era may ultimately result in clinical drug resistance and virologic failure [3-8].
- Published
- 2013